- Home
- BLRX vs AIMD Comparison
BLRX vs AIMD Comparison
Compare BLRX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- AIMD
- Stock Information
- Founded
- BLRX 2003
- AIMD 1984
- Country
- BLRX Israel
- AIMD United States
- Employees
- BLRX N/A
- AIMD N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- AIMD Health Care
- Exchange
- BLRX Nasdaq
- AIMD Nasdaq
- Market Cap
- BLRX 10.3M
- AIMD 9.9M
- IPO Year
- BLRX 2011
- AIMD N/A
- Fundamental
- Price
- BLRX $2.93
- AIMD $0.55
- Analyst Decision
- BLRX Buy
- AIMD
- Analyst Count
- BLRX 2
- AIMD 0
- Target Price
- BLRX $26.00
- AIMD N/A
- AVG Volume (30 Days)
- BLRX 30.2K
- AIMD 197.4K
- Earning Date
- BLRX 05-27-2025
- AIMD 05-12-2025
- Dividend Yield
- BLRX N/A
- AIMD N/A
- EPS Growth
- BLRX N/A
- AIMD N/A
- EPS
- BLRX N/A
- AIMD N/A
- Revenue
- BLRX $28,940,000.00
- AIMD $20,729.00
- Revenue This Year
- BLRX N/A
- AIMD N/A
- Revenue Next Year
- BLRX N/A
- AIMD N/A
- P/E Ratio
- BLRX N/A
- AIMD N/A
- Revenue Growth
- BLRX 502.92
- AIMD N/A
- 52 Week Low
- BLRX $2.30
- AIMD $0.40
- 52 Week High
- BLRX $35.60
- AIMD $1.46
- Technical
- Relative Strength Index (RSI)
- BLRX 48.07
- AIMD 52.35
- Support Level
- BLRX $2.30
- AIMD $0.52
- Resistance Level
- BLRX $3.09
- AIMD $0.59
- Average True Range (ATR)
- BLRX 0.22
- AIMD 0.05
- MACD
- BLRX 0.06
- AIMD 0.00
- Stochastic Oscillator
- BLRX 79.33
- AIMD 50.70
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.